Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say such results are just the start.
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.
PureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.
Shares in the Boston-based biotech creator, which had a standout success in forming Karuna Therapeutics, trade around cash levels — a "huge value disconnect" its leaders are trying to bridge.
The Fortis Life Sciences team will be presenting two posters on Friday, November 8, 2024 in the George R. Brown Convention Center, Level 1 – Exhibit Halls AB.
Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?
ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry and a portfolio company of Odyssey Investment Partners, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback